Which pancreatic enzyme replacement product (Zenpep (pancrelipase), Pancreaze (pancrelipase), Creon (pancrelipase), or Viokace (pancrelipase)) is the cheapest for a patient on a proton‑pump inhibitor or H2‑blocker, given insurance formulary and local pharmacy pricing?

Cost Comparison of Pancreatic Enzyme Products

The cost of pancreatic enzyme replacement therapy (PERT) products—Zenpep, Pancreaze, Creon, and Viokace—varies substantially based on individual insurance formulary coverage and local pharmacy pricing, making it impossible to definitively state which is cheapest without checking your specific insurance plan and pharmacy. 1

Key Clinical Context

All four products are therapeutically equivalent at similar lipase dosages, and the 2023 AGA guidelines explicitly state there is "generally no reason to switch from one to another based on response." 1 The drugs are equipotent, meaning clinical efficacy should not drive your choice—cost and insurance coverage should. 1

Important Distinction for Patients on Acid Suppressors

Since your patient is already on a PPI or H2-blocker:

• Zenpep, Pancreaze, and Creon are enteric-coated formulations that do NOT require acid suppression 1
• Viokace is the only non-enteric-coated formulation and requires mandatory co-treatment with a PPI or H2-blocker 1

This means Viokace is actually appropriate for your patient since they're already on acid suppression, whereas it would require an additional medication for patients not on PPIs/H2-blockers.

Practical Cost-Determination Strategy

Follow this algorithm to identify the cheapest option:

1. Check your patient's insurance formulary - Contact the pharmacy benefit manager or use the insurer's online formulary tool to determine:

   • Which products are covered (preferred vs. non-preferred tier)
   • Copay amounts for each product
   • Prior authorization requirements

2. Compare local pharmacy pricing - Call 2-3 pharmacies (including mail-order) with the specific dosage needed (typically starting at 40,000 lipase units per meal) 1

3. Investigate manufacturer assistance programs - All manufacturers offer patient-assistance programs that can substantially reduce out-of-pocket costs 1

4. Calculate total monthly cost including:

   • Medication copay
   • For Viokace users: they're already on PPI/H2-blocker, so no additional cost
   • For enteric-coated products: many patients are on PPIs anyway "for improving PERT efficacy" 1

Clinical Equivalence Evidence

Research confirms no meaningful efficacy differences between products when dosed appropriately:

• A 2016 head-to-head trial showed Zenpep and Creon (Kreon) were equivalent in fat absorption (84.1% vs 85.3%, p=0.297) 2
• A 2025 systematic review found no significant differences in coefficient of nitrogen absorption between Creon and Zenpep 3
• A 2013 analysis of 1,142 patients showed PERT efficacy is maintained regardless of concomitant PPI/H2RA use 4

Critical Pitfalls to Avoid

Do not assume generic equivalence - These are brand-name products with specific FDA-approved formulations. Over-the-counter pancreatic enzymes should never be used as they are unregulated dietary supplements with unknown efficacy and safety. 1

Do not let cost prevent treatment - The guidelines emphasize that "out-of-pocket costs can be quite substantial" and may make it "difficult for patients to obtain them even with patient-assistance programs." 1 Untreated EPI results in malnutrition, reduced quality of life, and increased mortality. 1

The "cheapest" option is whichever product your patient can actually afford and consistently take - A slightly more expensive product with better insurance coverage is cheaper than a nominally less expensive product the patient cannot afford.